Neo Medical and POCUS Certification Academy Launch Forward-Thinking Device and Education Bundle
'Knowledge and experience drive the use of any technology. This bundle provides both elements,' explained Jasmine Rockett, Director of POCUS Certification Academy. 'We deliver a foundation in ultrasound that allows a provider to feel confident in providing the best treatment for those in their care. Neo provides the best bridge for care for any provider looking to enhance their diagnostic ability and patient's experience at low expense.'
This novel solution educates healthcare professionals and validates their newly acquired POCUS skills in one accessible pathway. The bundle pairs Neo Medical's state-of-the-art, portable, and user-friendly wireless handheld ultrasound device with the POCUS Certification Academy's POCUS comprehensive, evidence-based Fundamentals Certificate curriculum.
This resource empowers clinicians at all levels—from beginners to advanced users—across any clinical specialty to confidently integrate ultrasound into their practice. The integration of device, and education improves diagnostic accuracy, patient care, and clinical outcomes. The bundle also supports healthcare institutions in standardizing the utilization of ultrasound, ensuring quality and consistency in patient care.
'Our vision is for all providers to have access to some level of ultrasound in their practice,' noted Rockett. 'The impact is significant – higher levels of care and patient satisfaction using the appropriate resources. This allows patients to feel better, faster, and have more confidence in their care plan.'
'We chose to partner with POCUS and Inteleos because they represent a critical component in what makes healthcare so effective – a certifiable, exceptional skill evaluated by experts across their specialties,' explained Mansoor Ghanavati, president of Neo Medical Inc. 'This focus creates an environment of highly skilled ultrasound providers who can quickly and reliably diagnose and treat conditions without the use of radiation.'
'Having ultrasound equipment only helps if you know how to use it, and having education only helps if you have the tools to practice with,' Kent Humerickhouse, Neo's Chief Marketing Officer explained. 'This collaboration between POCUS Certification Academy, Inteleos, and Neo Medical Inc. allows a provider the best environment for success. If we can make providers more knowledgeable in ultrasound, patient care outcomes are significantly improved.'
The Neo Medical POCUS Device & Fundamentals Certificate Bundle is now available to healthcare professionals worldwide through Neo Medical USA's website .
About Neo Medical, Inc.
Neo Medical Inc, specializes in crafting cutting-edge handheld and portable diagnostic ultrasound devices designed to bring advanced imaging technology directly to the point of care. Neo Medical's mission is to empower healthcare professionals with the mobility and precision they need to make timely and accurate diagnoses, no matter where they are.
About Point-of-Care-Ultrasound Academy
Point-of-Care Ultrasound (POCUS) Certification Academy offers globally recognized certifications for healthcare providers to independently validate their POCUS knowledge, application, and proficiency. POCUS partners with constituents through rigorous assessments, continual learning opportunities, and community building around important topics relevant to POCUS.
About Inteleos
Inteleos™ is a non-profit organization dedicated to ensuring equitable access to quality healthcare globally. It oversees the American Registry for Diagnostic Medical Sonography® (ARDMS®), the Alliance for Physician Certification & Advancement™ (APCA™), and the Point-of-Care Ultrasound Certification Academy™ (PCA), collectively representing 150,000+ certified medical professionals worldwide. The Inteleos Foundation manages the organization's philanthropic initiatives.
Contact:
Lisa Jordan
[email protected]
(240) 386-1579
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 days ago
- Business Wire
FUJIFILM Sonosite Redefines Superficial Imaging with the New UHF46-20 Transducer, the World's First 46MHz Ultra High Frequency Transducer for Point-of-Care Ultrasound
BOTHELL, Wash.--(BUSINESS WIRE)-- FUJIFILM Sonosite, Inc., the world leader in point-of-care ultrasound (POCUS) solutions, today announced a revolutionary advancement in point-of-care ultrasound imaging with the introduction of their UHF46-20 Transducer. This groundbreaking transducer is the first and only 46MHz Ultra-High Frequency (UHF) transducer available today in the point-of-care ultrasound market 1, setting a new standard for superficial image clarity and detail. With a minimum scan depth of 4mm, the UHF46-20 Transducer will enable clinicians to clearly visualize the first one to two centimeters beneath the skin and identify structures smaller than 1mm, such as superficial nerves and vessels, with high-quality resolution. Built upon the advanced Ultra High Frequency technology from FUJIFILM VisualSonics, and available exclusively on the FUJIFILM Sonosite LX POCUS system, this innovative technology provides the best superficial imaging 2,3,4 available on any point-of-care ultrasound system 1. 'At FUJIFILM Sonosite, we are driven by a commitment to help solve real-world challenges clinicians and providers face. The UHF46-20 transducer, when paired with the Sonosite LX system, enables the largest frequency range of any point-of-care ultrasound system on the market today - addressing a longstanding challenge that current clinical ultrasound systems have been unable to overcome,' said Richard Fabian, president and chief executive officer of FUJIFILM Sonosite, Inc. 'We're proud to bring to market the UHF46-20 Transducer as the first and only 46MHz UHF transducer in POCUS to provide clinicians with an unparalleled tool that may help them enhance diagnostic confidence and procedural accuracy.' The combination of the new transducer and the Sonosite LX offers clinicians a versatile solution for a wide spectrum of imaging needs, spanning from deep abdominal scans to ultra-high resolution superficial assessments. The UHF46-20 Transducer holds promise for improving outcomes across a range of sensitive applications including Neonatal Intensive Care Unit (NICU) and Rheumatology. In the NICU, its superior resolution may help clinicians see superficial submillimeter anatomy that conventional ultrasound may not capture. 6,11 The use of UHF ultrasound may aid clinicians in improving procedural quality by allowing for better visualization of tiny anatomy that may help to improve first attempt success rates. 4,8,9,10 In Rheumatology, UHF's advanced superficial imaging may aid in the visualization of subclinical synovitis, erosions, crystal deposits, and inflammation, all of which are beneficial in the early diagnosis and intervention of chronic conditions. 2,3,7 To learn more about the UHF46-20 Transducer, visit the product page at About FUJIFILM FUJIFILM Sonosite, Inc. is the innovator and world leader in bedside and point-of-care ultrasound, and an industry leader in ultra-high frequency micro-ultrasound technology. Headquartered near Seattle, the company is represented by a global distribution network in over 100 countries. Sonosite's portable, compact systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high-performance ultrasound to the point of patient care. For more information, please visit FUJIFILM Holdings Corporation, headquartered in Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver innovative products and services across the globe through the four key business segments of healthcare, electronics, business innovation, and imaging with over 70,000 employees. Guided and united by our Group Purpose of 'giving our world more smiles,' we address social challenges and create a positive impact on society through our products, services, and business operations. Under its medium-term management plan, VISION2030, which ends in FY2030, we aspire to continue our evolution into a company that creates value and smiles for various stakeholders as a collection of global leading businesses and achieve a global revenue of 4 trillion yen. For more information, please visit: References Internal Fujifilm research as of April 2025. Albano, D., Aringhieri, G., Messina, C., De Flaviis, L., & Sconfienza, L. M. (2020). High-Frequency and Ultra-High Frequency Ultrasound: Musculoskeletal Imaging up to 70 MHz. Seminars in musculoskeletal radiology, 24 (2), 125–134. Russo, A.; Reginelli, A.; Lacasella, G.V.; Grassi, E.; Karaboue, M.A.A.; Quarto, T.; Busetto, G.M.; Aliprandi, A.; Grassi, R.; Berritto, D. Clinical Application of Ultra-HighFrequency Ultrasound. J. Pers. Med. 2022, 12, 1733. 10.3390/jpm12101733 Ait Ichou, J., Gauvin, S., & Faingold, R. (2021). Ultra-high-frequency ultrasound of superficial and musculoskeletal structures in the pediatric population. Pediatric radiology, 51 (9), 1748–1757. Hayashi, A., Giacalone, G., Yamamoto, T., Belva, F., Visconti, G., Hayashi, N., Handa, M., Yoshimatsu, H., & Salgarello, M. (2019). Ultra High-frequency Ultrasonographic Imaging with 70 MHz Scanner for Visualization of the Lymphatic Vessels. Plastic and reconstructive surgery. Global open, 7 (1), e2086. Latham, G. J., Veneracion, M. L., Joffe, D. C., Bosenberg, A. T., Flack, S. H., & Low, D. K. (2013). High-frequency micro-ultrasound for vascular access in young children--a feasibility study by the High-frequency UltraSound in Kids studY (HUSKY) group. Paediatric anaesthesia, 23 (6), 529–535. Viviano, S. L., Chandler, L. K., & Keith, J. D. (2018). Ultrahigh Frequency Ultrasound Imaging of the Hand: A New Diagnostic Tool for Hand Surgery. Hand (New York, N.Y.), 13(6), 720–725. Jacobsen RB, Hebelka H, Gatzinsky V, Elfvin A, Dangardt F. Ultra-high-frequency ultrasound (48–70 MHz) is a promising tool for improved gastrointestinal diagnostics in infants. Acta Paediatr. 2024; 113: 2304–2311. Brusciano, V., & Lecce, M. (2024). Advantages of the use of ultrasound in newborn vascular access: a systematic review. Journal of ultrasound, 27 (2), 203–207. Currie M, Vashisht R, Elkin D, et al. Ultrasound Intravascular Access. [Updated 2024 Jul 2]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: Salvia, G.; Zerbinati, N.; Manzo Margiotta, F.; Michelucci, A.; Granieri, G.; Fidanzi, C.; Morganti, R.; Romanelli, M.; Dini, V. Ultra-High-Frequency Ultrasound as an Innovative Imaging Evaluation of Hyaluronic Acid Filler in Nasolabial Folds. Diagnostics 2023, 13, 2761. diagnostics13172761 Hawez, T., Evertsson, M., Erlöv, T. et al. The use of ultra-high frequency ultrasound in identifying aganglionosis in Hirschsprung's disease. Sci Rep 15, 15124 (2025).
WIRED
17-07-2025
- WIRED
Taste the Future With the Best Meal Replacement Shakes
Flavor Texture Satiety TOTAL 7.1 6.4 6.8 6.8 OWYN stands for 'only what you need,' which feels similar to the pitch Dozer gives Neo in The Matrix as he sets our hero up with a bowl of protein-rich slop for his first meal after being yanked back into what's left of the real world. OWYN does offer a caffeinated version of its protein shakes, but this iteration merely references coffee in name and flavor. The liquid is thin and easy enough to put down, with a tingle of artificial sweetener on the finish that quickly gives way to a coffee flavor that's not unlike something you'd taste at a janky ice cream stand that offers something like 'Jim's Jacked-Up Java' as the milkshake flavor of the month. The slim stats in the protein and fat categories combined with the coffee-adjacent placebo had me feeling shaky and malnourished by 10 am most days when I replaced my breakfast with OWYN. This is not a great pick if you're trying to go the distance without chewing or even thinking about procuring a proper meal, but it could be a nice post-lunch boost that does an OK job of scratching the itch for a sweet coffee treat. Top off your actual cold brew with this coffee-flavored glurp if you're feeling naughty, or you can toss what's left of your McDonald's coffee from the drive to work into the fridge, then mix it around with a bottle of OWYN a few hours later if you're feeling downright trashy. Cost per serving: $33.29 per 12 pack = $2.75 Other flavors available: Cookies & Creamless, Dark Chocolate, Smooth Vanilla, Strawberry Banana Allergens: None; bottle alleges each batch is 'independently tested for detection of the top nine allergens' Protein: 20 g Calories: 180 (12 oz RTD bottle) Carbs: 8 g Fat: 7 g Caffeine: No $40 $37 (8% off) Amazon (30 servings) Flavor Texture Satiety TOTAL 8.7 6.2 7.1 7.3 One can learn a lot about a health brand by its collab co-signs. Since its founding in 2016 by recovering addict/ex-con/ur-patriot Aaron Singerman, Redcon1 has hitched its star to Nascar and the US military, along with junk-food brands like Hostess and the newly revitalized soda brand Jolt Cola. This handily explains its expansive selection of kooky supplement flavors, which are essentially drinkable pastries that allege to help you get swole. When prepared per the suggestion of its packaging, the combo of about 30 grams of cookies 'n' cream powder mixed with 6 ounces of water yields a thick beige liquid that's punctuated by little black clumps of cookie dust. It's as weird as it is tasty, and if I weren't already the type of person who thought a selfie in front of an Arby's was a solid Tinder profile pic, I would probably be ashamed to like this as much as I did. Once you get used to the sweet and dusty bits of cookie that bust open when you chew them, this is a fun ride for anyone who can hang. Redcon1's MRE series is technically a protein powder, but it's heavy on protein for its rather diminutive calorie count, making it a fine meal replacement assuming you have a salad or some other fibrous food item on deck for lunch or dinner. One 6-ounce glass of this candy-like slurry filled me right up in the morning, and I was good to go until salad time rolled around at noon. Cost per serving: Around $1 Other flavors available: Banana Nut Bread, Blueberry Cobbler, Chocolate, Chocolate Mousse, Fudge Brownie, Oatmeal Chocolate Chip, Peanut Butter Cookie, Peanut Butter Chocolate Cheesecake, Snickerdoodle, Strawberry Shortcake, Vanilla Milkshake Allergens: Milk, egg, fish, tree nuts, wheat, soy Protein: 24 g Calories: 130 Carbs: 4 g Fat: 2 g Caffeine: No
Yahoo
18-06-2025
- Yahoo
Exo Launches a New Era in Disease Diagnosis with the First FDA-cleared Ultrasound AI for Detection of Pleural Effusion and Consolidation/Atelectasis
Exo Iris® now automatically detects and localizes key pulmonary findings for emergency care, showing superiority to clinicians alone SANTA CLARA, Calif., June 18, 2025--(BUSINESS WIRE)--Exo (pronounced "echo"), the leader in AI-powered, accessible medical imaging, is transforming lung disease diagnosis with another first. Now included on Exo Iris® is the first ever FDA 510(k) cleared AI for detecting pleural effusion and consolidation/atelectasis. These on-device real-time indicators empower clinicians with objective data to help detect lung diseases like pneumonia and tuberculosis at the bedside in seconds. Arun Nagdev, MD, Vice President of Clinical Affairs at Exo and a leading POCUS expert, said, "This groundbreaking real-time AI provides a remarkable assist for all clinicians at the bedside, instantly and accurately detecting fluid around the lungs or areas of collapsed lung, key markers for significant infections like pneumonia or tuberculosis. This is a great support for clinicians looking to diagnose commonly presenting patient symptoms of shortness of breath, coughing, pain, and fatigue." Said Dornoosh Zonoobi, VP of AI at Exo, "Validated in rigorous clinical studies, these AIs enabled clinicians to detect key lung findings, with sensitivity and specificity in the 'excellent' range. We're thrilled to bring these FDA-cleared firsts to all clinicians and to meaningfully impact patient diagnosis and outcomes when it matters most." These clearances mark not only a technical and regulatory milestone, but a meaningful expansion in how Exo is supporting frontline providers and patients when every second counts. Exo remains focused on delivering technology that enables critical decisions instantly, intelligently, and saves lives at scale. These clearances bring to a remarkable 14, the FDA-cleared AI indicators embedded in Iris. This sweeping portfolio is unmatched in handheld ultrasound today. All commercialized Exo AI runs directly on Exo Iris®, operates without internet, eliminates lag, and enables expert-level diagnostics in any setting. Exo is establishing a new standard in fast, accurate, and scalable point-of-care imaging. Visit Exo's website to explore these capabilities. About Exo Exo is redefining medical imaging with its advanced ultrasound platform, combining novel silicon-based hardware, tightly coupled AI, and easy-to-use collaboration software. Its handheld and soon-to-be OEM-integrated systems deliver high-performance imaging and real-time clinical intelligence, driving better, more accessible diagnostics and outcomes across diverse care settings. Follow us at @exoeffect on X, LinkedIn, Facebook, and Instagram. View source version on Contacts media@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
